ArriVent BioPharma, Inc. (AVBP)
| Market Cap | 824.92M -2.3% |
| Revenue (ttm) | n/a |
| Net Income | -164.21M |
| EPS | -3.70 |
| Shares Out | 49.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,731,729 |
| Open | 16.59 |
| Previous Close | 16.71 |
| Day's Range | 16.49 - 17.76 |
| 52-Week Range | 11.36 - 35.83 |
| Beta | 1.35 |
| Analysts | Strong Buy |
| Price Target | 20.56 (+22.89%) |
| Est. Earnings | Nov 9, 2026 |
About AVBP
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for AVBP stock is "Strong Buy." The 12-month stock price target is $20.56, which is an increase of 22.89% from the latest price.
News
ArriVent Biopharma price target lowered to $27 from $47 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns lowered the firm’s price target on ArriVent Biopharma (AVBP) to $27 from $47 and keeps a Buy rating on the shares following the FURVENT trial…
AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $AVBP--AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law.
AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma
AVBP was down 56.7% before the opening bell and traded as low as $12.09 after ArriVent disclosed that its Phase 3 FURVENT trial of firmonertinib missed its primary endpoint. An investigation into pote...
ArriVent Biopharma price target lowered to $29 from $42 at BTIG
BTIG analyst Jeet Mukherjee lowered the firm’s price target on ArriVent Biopharma (AVBP) to $29 from $42 and keeps a Buy rating on the shares after the FURVENT Phase 3…
ArriVent Biopharma price target lowered to $18 from $45 at Guggenheim
Guggenheim lowered the firm’s price target on ArriVent Biopharma (AVBP) to $18 from $45 and keeps a Buy rating on the shares after the FURVENT Phase 3 trial evaluating firmonertinib…
ArriVent Biopharma price target lowered to $20 from $40 at Citi
Citi lowered the firm’s price target on ArriVent Biopharma (AVBP) to $20 from $40 and keeps a Buy rating on the shares. The firm removed firmonertinib’ in frontline exon 20…
ArriVent Biopharma price target lowered to $22 from $47 at Clear Street
Clear Street lowered the firm’s price target on ArriVent Biopharma (AVBP) to $22 from $47 and keeps a Buy rating on the shares. Firmonertinib’s Phase 3 FURVENT miss was primarily…
ArriVent Biopharma price target lowered to $22 from $45 at Jones
Jones lowered the firm’s price target on ArriVent Biopharma (AVBP) to $22 from $45 and keeps a Buy rating on the shares. The company’s Phase III failed to meet the…
ArriVent Biopharma price target lowered to $18 from $45 at Truist
Truist lowered the firm’s price target on ArriVent Biopharma (AVBP) to $18 from $45 and keeps a Buy rating on the shares. The company disclosed this morning that FURVENT missed…
ArriVent Biopharma price target lowered to $18 from $45 at Jefferies
Jefferies lowered the firm’s price target on ArriVent Biopharma (AVBP) to $18 from $45 and keeps a Buy rating on the shares after the company announced that the FURVENT Phase…
ArriVent says Phase 3 firmonertinib trial did not meet endpoint
ArriVent BioPharma (AVBP) announced that the FURVENT Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, locally advanced or metastatic non-squamous non-small cel...
ArriVent's oral lung cancer therapy fails late-stage trial, shares plunge
ArriVent BioPharma said on Tuesday its oral therapy to treat patients with a rare type of lung cancer did not meet the main goal of delaying disease progression in a late-stage trial, sending shares...
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
NEWTOWN SQUARE, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innov...
ArriVent Biopharma granted orphan designation for pancreatic cancer treatment
The FDA granted ArriVent BioPharma (AVBP) orphan designation for a treatment of pancreatic cancer, according to a post to the agency’s website.
ArriVent Biopharma price target raised to $47 from $44 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on ArriVent Biopharma (AVBP) to $47 from $44 and keeps a Buy rating on the shares following the Q2 report. The firm reduced…
ArriVent Biopharma price target lowered to $40 from $43 at Citi
Citi analyst Yigal Nochomovitz lowered the firm’s price target on ArriVent Biopharma (AVBP) to $40 from $43 and keeps a Buy rating on the shares. The company now expects the…
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innov...
ArriVent BioPharma Earnings release: Q2 2026
ArriVent BioPharma released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
ArriVent BioPharma Quarterly report: Q2 2026
ArriVent BioPharma has published its Q2 2026 quarterly earnings report on August 12, 2026.
ArriVent BioPharma Slides: Corporate presentation
ArriVent BioPharma has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
ArriVent BioPharma Transcript: AGM 2026
The meeting confirmed a quorum and proceeded virtually, electing three directors for terms ending in 2029 and ratifying PricewaterhouseCoopers LLP as auditor for 2026. No questions were received from stockholders during the Q&A session.
ArriVent Biopharma assumed with a Buy at Truist
Truist assumed coverage of ArriVent Biopharma (AVBP) with a Buy rating with a price target of $45, up from $43. The firm views the company’s firmo – firmonertinib – as…
ArriVent Biopharma price target lowered to $43 from $45 at Citi
Citi lowered the firm’s price target on ArriVent Biopharma (AVBP) to $43 from $45 and keeps a Buy rating on the shares.
ArriVent Biopharma reports Q1 EPS (96c), consensus (89c)
“Our two ongoing pivotal firmonertinib trials in uncommon EGFR-mutant non-small cell lung cancer continue to advance, with topline monotherapy data for frontline EGFR exon 20 insertion mutations expec...
ArriVent BioPharma Reports First Quarter 2026 Financial Results
NEWTOWN SQUARE, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innova...